WHWK
Whitehawk Therapeutics Inc
Biotechnology
Market Cap$206M
5Y Perf.-77.8%
Build Your Comparison
Side-by-side financial analysisWHWK
ACAD
AXSM
Try popular comparisons:
Stock Comparison
WHWK vs ACAD vs AXSM
Revenue, margins, valuation, and 5-year total return — side by side.
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.61B
5Y Perf.-56.5%
AXSM
Axsome Therapeutics, Inc.
Biotechnology
Market Cap$13.13B
5Y Perf.+210.1%
WHWK vs ACAD vs AXSM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  WHWK |  ACAD |  AXSM |
|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $206M | $3.61B | $13.13B |
| Revenue (TTM) | $7M | $1.10B | $708M |
| Net Income (TTM) | $-21M | $376M | $-188M |
| Gross Margin | 89.3% | 91.5% | 92.6% |
| Operating Margin | -16.0% | 7.4% | -24.8% |
| Forward P/E | — | 54.2x | — |
| Total Debt | $0.00 | $52M | $241M |
| Cash & Equiv. | $38M | $178M | $323M |
WHWK vs ACAD vs AXSM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WHWK
ACAD
AXSM
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Whitehawk Therapeut… (WHWK) | 100 | 22.2 | -77.8% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 43.5 | -56.5% |
| Axsome Therapeutics… (AXSM) | 100 | 310.1 | +210.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WHWK vs ACAD vs AXSM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AXSM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇AXSM emerged as the overall leader. Track its performance:
WHWK
Whitehawk Therapeutics Inc
The Secondary Option
WHWK plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ACAD
ACADIA Pharmaceuticals Inc.
The Defensive Pick
ACAD is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.10, Low D/E 4.3%, current ratio 3.83x
- 34.3% margin vs WHWK's -288.3%
- 26.2% ROA vs AXSM's -27.8%, ROIC 10.0% vs -19.1%
Best for: sleep-well-at-night
AXSM
Axsome Therapeutics, Inc.
The Income Pick
AXSM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.63
- Rev growth 65.5%, EPS growth 38.6%, 3Y rev CAGR 133.7%
- 35.5% 10Y total return vs ACAD's -44.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  AXSM | 65.5% revenue growth vs WHWK's -72.5% |
| Quality / Margins |  ACAD | 34.3% margin vs WHWK's -288.3% |
| Stability / Safety | AXSM | Beta 0.63 vs WHWK's 1.68 |
| Dividends | Tie | None of these 3 stocks pay a meaningful dividend |
| Momentum (1Y) | AXSM | +140.2% vs ACAD's -3.0% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs AXSM's -27.8%, ROIC 10.0% vs -19.1% |
WHWK vs ACAD vs AXSM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2018
FY 2025
WHWK vs ACAD vs AXSM — Financial Metrics
Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGWHWK
Who Leads Where
ACAD leads in 2 of 6 categories
AXSM leads 2 • WHWK leads 0 • 1 tied
Explore the data ↓WHWKWhitehawk Therapeutic…
0leads
AXSMAxsome Therapeutics, …
2leads
ACADACADIA Pharmaceutical…
2leads
6 Total Categories
CATEGORYLEADERvs AXSMvs WHWKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
AXSM5/6
Risk & VolatilityBeta, volatility, and downside exposure
AXSM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD is the larger business by revenue, generating $1.1B annually — 153.3x WHWK's $7M. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to WHWK's -2.9%. On growth, AXSM holds the edge at +57.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| RevenueTrailing 12 months | $7M | $1.1B | $708M |
| EBITDAEarnings before interest/tax | -$114M | $96M | -$167M |
| Net IncomeAfter-tax profit | -$21M | $376M | -$188M |
| Free Cash FlowCash after capex | -$98M | $212M | -$71M |
| Gross MarginGross profit ÷ Revenue | +89.3% | +91.5% | +92.6% |
| Operating MarginEBIT ÷ Revenue | -16.0% | +7.4% | -24.8% |
| Net MarginNet income ÷ Revenue | -2.9% | +34.3% | -26.6% |
| FCF MarginFCF ÷ Revenue | -13.7% | +19.4% | -10.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +9.7% | +57.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +49.3% | -81.8% | -3.3% |
ACAD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — WHWK and ACAD and AXSM each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| Market CapShares × price | $206M | $3.6B | $13.1B |
| Enterprise ValueMkt cap + debt − cash | $168M | $3.5B | $13.0B |
| Trailing P/EPrice ÷ TTM EPS | -12.61x | 9.21x | -69.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 54.20x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 25.09x | — |
| Price / SalesMarket cap ÷ Revenue | 28.79x | 3.37x | 20.57x |
| Price / BookPrice ÷ Book value/share | 1.89x | 2.94x | 143.77x |
| Price / FCFMarket cap ÷ FCF | — | 34.34x | — |
Evenly matched — WHWK and ACAD and AXSM each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-3 for AXSM. ACAD carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to AXSM's 2.73x. On the Piotroski fundamental quality scale (0–9), ACAD scores 6/9 vs WHWK's 3/9, reflecting solid financial health.
| Metric | WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| ROE (TTM)Return on equity | -12.0% | +35.6% | -2.6% |
| ROA (TTM)Return on assets | -11.2% | +26.2% | -27.8% |
| ROICReturn on invested capital | -139.1% | +10.0% | -19.1% |
| ROCEReturn on capital employed | -120.7% | +10.1% | -52.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 | 4 |
| Debt / EquityFinancial leverage | — | 0.04x | 2.73x |
| Net DebtTotal debt minus cash | -$38M | -$126M | -$82M |
| Cash & Equiv.Liquid assets | $38M | $178M | $323M |
| Total DebtShort + long-term debt | $0 | $52M | $241M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -34.13x |
ACAD leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
AXSM leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AXSM five years ago would be worth $37,792 today (with dividends reinvested), compared to $1,401 for WHWK. Over the past 12 months, AXSM leads with a +140.2% total return vs ACAD's -3.0%. The 3-year compound annual growth rate (CAGR) favors AXSM at 50.5% vs WHWK's -19.1% — a key indicator of consistent wealth creation.
| Metric | WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| YTD ReturnYear-to-date | +70.5% | -19.3% | +42.8% |
| 1-Year ReturnPast 12 months | +103.9% | -3.0% | +140.2% |
| 3-Year ReturnCumulative with dividends | -47.1% | -14.3% | +241.0% |
| 5-Year ReturnCumulative with dividends | -86.0% | -22.6% | +277.9% |
| 10-Year ReturnCumulative with dividends | -95.4% | -44.6% | +3550.5% |
| CAGR (3Y)Annualised 3-year return | -19.1% | -5.0% | +50.5% |
AXSM leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
AXSM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AXSM is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than WHWK's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AXSM currently trades 98.9% from its 52-week high vs WHWK's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 1.10x | 0.63x |
| 52-Week HighHighest price in past year | $5.50 | $27.81 | $257.93 |
| 52-Week LowLowest price in past year | $1.57 | $19.69 | $96.09 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +75.8% | +98.9% |
| RSI (14)Momentum oscillator 0–100 | 45.5 | 47.9 | 73.6 |
| Avg Volume (50D)Average daily shares traded | 331K | 1.4M | 690K |
AXSM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ACAD as "Buy", AXSM as "Buy". Consensus price targets imply 68.3% upside for WHWK (target: $7) vs 2.8% for AXSM (target: $262).
| Metric | WHWKWhitehawk Therape… | ACADACADIA Pharmaceut… | AXSMAxsome Therapeuti… |
|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy |
| Price TargetConsensus 12-month target | $7.00 | $34.78 | $262.38 |
| # AnalystsCovering analysts | — | 37 | 25 |
| Dividend YieldAnnual dividend ÷ price | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — |
| Dividend / ShareAnnual DPS | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AXSM leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 2 of 6 categories
Loading custom metrics...
WHWK vs ACAD vs AXSM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is WHWK or ACAD or AXSM a better buy right now?
For growth investors, Axsome Therapeutics, Inc.
(AXSM) is the stronger pick with 65. 5% revenue growth year-over-year, versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 2x trailing P/E (54. 2x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — WHWK or ACAD or AXSM?
Over the past 5 years, Axsome Therapeutics, Inc.
(AXSM) delivered a total return of +277. 9%, compared to -86. 0% for Whitehawk Therapeutics Inc (WHWK). Over 10 years, the gap is even starker: AXSM returned +35. 5% versus WHWK's -95. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — WHWK or ACAD or AXSM?
By beta (market sensitivity over 5 years), Axsome Therapeutics, Inc.
(AXSM) is the lower-risk stock at 0. 63β versus Whitehawk Therapeutics Inc's 1. 68β — meaning WHWK is approximately 166% more volatile than AXSM relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 3% for Axsome Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — WHWK or ACAD or AXSM?
By revenue growth (latest reported year), Axsome Therapeutics, Inc.
(AXSM) is pulling ahead at 65. 5% versus -72. 5% for Whitehawk Therapeutics Inc (WHWK). On earnings-per-share growth, the picture is similar: Whitehawk Therapeutics Inc grew EPS 86. 0% year-over-year, compared to 38. 6% for Axsome Therapeutics, Inc.. Over a 3-year CAGR, AXSM leads at 133. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — WHWK or ACAD or AXSM?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -288. 3% for Whitehawk Therapeutics Inc — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -1601. 1% for WHWK. At the gross margin level — before operating expenses — AXSM leads at 92. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is WHWK or ACAD or AXSM more undervalued right now?
Analyst consensus price targets imply the most upside for WHWK: 68.
3% to $7. 00.
07Which pays a better dividend — WHWK or ACAD or AXSM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is WHWK or ACAD or AXSM better for a retirement portfolio?
For long-horizon retirement investors, Axsome Therapeutics, Inc.
(AXSM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63)). Whitehawk Therapeutics Inc (WHWK) carries a higher beta of 1. 68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AXSM: +35. 5%, WHWK: -95. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between WHWK and ACAD and AXSM?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: WHWK is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; AXSM is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.